In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors

In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors Publisher

Asadighalehni M¹ ; Rasaee MJ² ; Khosravani M³ ; Bazl MR⁴ ; Mohamadi M¹ ; Fatemi F¹ ; Sadroddiny E¹

Source: Biosciences Biotechnology Research Asia Published:2015

Abstract

The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). EGFR over expressed in different cancers like neck, lung and breast. Various approaches have been used to activate the immune system against EGFR+ cancer such as vaccine therapy. Herein a recombinant fusion peptide composed of EGFR mimotope and L2 domain of EGFR designed. Using in silico studies the potency of the peptide as a vaccine evaluated. This peptide was then cloned into an expression vector and expressed in E. Coli. The ELISA results of the purified peptide against anti EGFR antibodies showed that this peptide could be functional as a vaccine candidate against EGFR-positive tumors.

Related Docs

View other Related Docs

1. A Novel Recombinant Anti-Epidermal Growth Factor Receptor Peptide Vaccine Capable of Active Immunization and Reduction of Tumor Volume in a Mouse Model, Microbiology and Immunology (2017)

2. Construction of a Recombinant Phage-Vaccine Capable of Reducing the Growth Rate of an Established Ll2 Tumor Model, Iranian Journal of Allergy# Asthma and Immunology (2018)

3. A Novel Tumor Inhibitory Hybridoma Monoclonal Antibody With Dual Specificity for Her3 and Her2, Current Research in Translational Medicine (2021)

Experts (# of related papers)

View all Related Experts

Forough Golsaz Shirazi (3)

Mohammad Mehdi Amiri (3)

Style	Citing Format
MLA	Asadighalehni M, et al.. "In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors." Biosciences Biotechnology Research Asia, vol. 12, no. 3, 2015, pp. 2405-2410.
APA	Asadighalehni M, Rasaee MJ, Khosravani M, Bazl MR, Mohamadi M, Fatemi F, Sadroddiny E (2015). In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors. Biosciences Biotechnology Research Asia, 12(3), 2405-2410.
Chicago	Asadighalehni M, Rasaee MJ, Khosravani M, Bazl MR, Mohamadi M, Fatemi F, Sadroddiny E. "In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors." Biosciences Biotechnology Research Asia 12, no. 3 (2015): 2405-2410.
Harvard	Asadighalehni M et al. (2015) 'In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors', Biosciences Biotechnology Research Asia, 12(3), pp. 2405-2410.
Vancouver	Asadighalehni M, Rasaee MJ, Khosravani M, Bazl MR, Mohamadi M, Fatemi F, et al.. In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors. Biosciences Biotechnology Research Asia. 2015;12(3):2405-2410.
BibTex	@article{ author = {Asadighalehni M and Rasaee MJ and Khosravani M and Bazl MR and Mohamadi M and Fatemi F and Sadroddiny E}, title = {In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors}, journal = {Biosciences Biotechnology Research Asia}, volume = {12}, number = {3}, pages = {2405-2410}, year = {2015} }
RIS	TY - JOUR AU - Asadighalehni M AU - Rasaee MJ AU - Khosravani M AU - Bazl MR AU - Mohamadi M AU - Fatemi F AU - Sadroddiny E TI - In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors JO - Biosciences Biotechnology Research Asia VL - 12 IS - 3 SP - 2405 EP - 2410 PY - 2015 ER -

Science Communicator Platform

Authors

Abstract